NTRK1 and leukemia: Following the FDA approval of entrectinib [174] for the treatment of patients with solid tumors presenting with a NTRK gene fusion, the RNA-seq studies have identified the gene fusions involving NTRK in leukemias that exhibit a high sensitivity to TRK inhibition in mouse models, thus opening the door to new therapeutic opportunities with TRK inhibitors for leukemia patients who exhibit gene fusions involving NTRK [175,176].